Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Absence of a pharmacokinetic interaction between enalapril and frusemide.

Literature DB >> 3028456

Absence of a pharmacokinetic interaction between enalapril and frusemide.

A M Van Hecken, R Verbesselt, A Buntinx, V J Cirillo, P J De Schepper.

Abstract

Single doses of enalapril maleate 10 mg and frusemide 80 mg do not significantly affect the pharmacokinetics of each other when taken concomitantly. Their concomitant use may be associated with more adverse effects than with the individual entities.

Entities: Chemical

Mesh：

Substances：
Enalapril
Furosemide

Year: 1987 PMID： 3028456 PMCID： PMC1386144 DOI： 10.1111/j.1365-2125.1987.tb03013.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

12 in total

1. Measurement of furosemide by high-performance liquid chromatography.

Authors: S E Swezey; P J Meffin; T F Blaschke
Journal: J Chromatogr Date: 1979-07-01

2. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.

Authors: C S Sweet; D M Gross; P T Arbegast; S L Gaul; P M Britt; C T Ludden; D Weitz; C A Stone
Journal: J Pharmacol Exp Ther Date: 1981-03 Impact factor: 4.030

3. Determining the probability of an important difference in bioavailability.

Authors: B E Rodda; R L Davis
Journal: Clin Pharmacol Ther Date: 1980-08 Impact factor: 6.875

4. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.

Authors: R A Lewis; K M Baker; C R Ayers; B A Weaver; M R Lehman
Journal: J Cardiovasc Pharmacol Date: 1985 Impact factor: 3.105

5. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.

Authors: F Andreasen; C K Christensen; F K Jakobsen; C E Mogensen
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1981-09

6. Effects of enalapril, a new converting enzyme inhibitor, in hypertension.

Authors: R K Ferguson; P H Vlasses; B N Swanson; P Mojaverian; M Hichens; J D Irvin; P B Huber
Journal: Clin Pharmacol Ther Date: 1982-07 Impact factor: 6.875

7. Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension.

Authors: P A Freier; G L Wollam; W D Hall; D J Unger; M B Douglas; R P Bain
Journal: Clin Pharmacol Ther Date: 1984-12 Impact factor: 6.875

8. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations.

Authors: L DiCarlo; K Chatterjee; W W Parmley; K Swedberg; B Atherton; D Curran; M Cucci
Journal: J Am Coll Cardiol Date: 1983-11 Impact factor: 24.094

7. Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of the rat kidney. VI. Specificity: amino acids, their N-methyl-, N-acetyl- and N-benzoylderivatives; glutathione- and cysteine conjugates, di- and oligopeptides.

Authors: K J Ullrich; G Rumrich; T Wieland; W Dekant
Journal: Pflugers Arch Date: 1989-12 Impact factor: 3.657

7 in total

Absence of a pharmacokinetic interaction between enalapril and frusemide.

1. Measurement of furosemide by high-performance liquid chromatography.

2. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.

3. Determining the probability of an important difference in bioavailability.

4. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.

5. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.

6. Effects of enalapril, a new converting enzyme inhibitor, in hypertension.

7. Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension.

8. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations.

9. Implications of intraindividual variability in bioavailability studies of furosemide.

10. The clinical pharmacology of enalapril.

1. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.

Review 2. ACE inhibitors. Drug interactions of clinical significance.

3. Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects.

Review 4. Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.

Review 5. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Review 6. Pharmacokinetic drug interactions with ACE inhibitors.

7. Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of the rat kidney. VI. Specificity: amino acids, their N-methyl-, N-acetyl- and N-benzoylderivatives; glutathione- and cysteine conjugates, di- and oligopeptides.